DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET. A live webcast of the presentation will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl ...

Core Viewpoint - Karolinska Development AB's portfolio company OssDsign successfully completed a directed share issue, raising approximately SEK 158 million, and announced an updated strategy and revised financial targets for 2025–2028 [1][3]. Group 1: Directed Share Issue - OssDsign's directed share issue attracted both existing and new institutional investors, including Adrigo Asset Management and La financiere de L'Echiquier, with the subscription price determined through an accelerated bookbuilding procedure [2][3]. - The successful share issue is expected to strengthen OssDsign's efforts in accelerating sales growth and building a long-term profitable business [3]. Group 2: Updated Strategy and Financial Targets - The new strategy, "ScaleToProfit," focuses on investments in four main areas: sales and marketing, research and development, clinical studies, and production [3][8]. - Revised financial targets include achieving sales of over SEK 400 million by 2028, which represents a compounded annual growth rate of over 30% during 2025–2028, and becoming EBIT profitable and cash flow positive in the second half of 2025–2028 [8]. Group 3: Company Overview - Karolinska Development holds a 3% ownership stake in OssDsign [4]. - The company is a Nordic life sciences investment firm that identifies and invests in breakthrough medical innovations, aiming to create and grow companies that advance these innovations into commercial products [5][6]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [7].